Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | STS | P08842 | 1/20 | 0.55 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3813935 | 0.90 | L3MBTL1 (0.64) | L3MBTL1NPC1STSHSD17B3PLA2G4B | |
| SCHEMBL15199293 | 0.87 | L3MBTL1 (0.60) | L3MBTL1NPC1STSHSD17B3PLA2G4B | |
| SCHEMBL7929301 | 0.86 | MEN1 (0.58) | L3MBTL1NPC1SMN1; SMN2ALOX15ALDH1A1 | |
| SCHEMBL11661633 | 0.83 | L3MBTL1 (0.55) | L3MBTL1NPC1STSHSD17B3SMN1; SMN2 | |
| SCHEMBL7336923 | 0.83 | ALOX15 (0.53) | L3MBTL1NPC1SMN1; SMN2ALOX15ALDH1A1 | |
| SCHEMBL13753195 | 0.82 | L3MBTL1 (0.77) | L3MBTL1NPC1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL8381238 | 0.81 | NPC1 (0.56) | L3MBTL1NPC1SMN1; SMN2ALOX15ALDH1A1 | |
| SCHEMBL4666309 | 0.81 | LMNA (0.58) | HPGDALOX15PLA2G4B | |
| SCHEMBL8828412 | 0.80 | ALOX15 (0.59) | NPC1SMN1; SMN2ALOX15ALDH1A1TSHR | |
| SCHEMBL1291801 | 0.79 | L3MBTL1 (0.68) | L3MBTL1NPC1STSHSD17B3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951217-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20080234199-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-25 | — | — | US | disclosed |
| EP-1951043-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1951217-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007062067-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062148-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234199-A1 | Chemical Compounds | GPER1, ESR2, ESR1 | L3MBTL1 4673/4885NPC1 717/4885STS 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.